This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

Figure 1, pg. 1 of 3


Human G Protein Coupled Receptor Family (Receptors known as of January, 1999)

FIGURE 1

	TOR(S):														SH	EET	1 0	F 60		n's						
THERAPEUTICS	,	-		Acuity, Alzheimer's		Diabetes, Cardiovascular	Cardiovascular, Respiratory	Cardiovascular, Parkinson's	Anti-inflammatory, Ulcers	Depression, Insomnia, Analgesic		Cardiovascular, Endocrine	Anti-inflammatory, Asthma	Anti-inflammatory	Anti-inflammatory	Anti-inflammatory	Anti-inflammatory		Airway Diseases, Anesthetic	Gastrointestinal, Obesity, Parkinson's	Cardiovascular, Respiratory	Anti-inflammatory, Analgesics	Behavior, Memory, Cardiovascular	Cardiovascular, Analgesic	Depression, Analgesic	Oncology, Alzheimer's
PHYSIOLOGY				Neurotransmitter		Gluconeogenesis	Muscle Contraction	Neurotransmitter	Vascular Permeability	Neurotransmitter		Vasoconstriction	Vasodilation,	Immune System	Chemoattractant	Chemoattractant	Chemoattractant	Fat Metabolism	Bronchodilator, Pain	Motility, Fat Absorption	Muscle Contraction	Metabolic Regulation	Neurotransmitter	CNS	CNS	Neurotransmitter
TISSUE				Brain, Nerves, Heart		Brain, Kidney, Lung	Kidney, Heart	Brain, Kidney, GI	Vascular, Heart, Brain	Most Tissues		Vascular, Liver, Kidney	Liver, Blood	Blood	Blood	Blood	Blood	Brain	Brain	Gastrointestinal	Heart, Bronchus, Brain	Kidney, Brain	Nerves, Intestine, Blood	Brain,	Brain,	Brain, Gastrointestinal
NUMBER				nic) 5		9	3	5	2	16		. 2	1	1	8		9	2	1	2	2	5	ς.	1	33	5
LIGAND		•Amine	·Acetylcholine	(muscarinic & nicotinic)	·Adrenoceptors	·Alpha Adrenoceptors	·Beta Adrenoceptors	Dopamine.	·Histamine	·Serotonin (5-HT)	•Peptide	Angiotensin	Bradykinin	·C5a anaphylatoxin	·Fmet-leu-phe	Interleukin-8	·Chemokine	·Orexin	·Nociceptin	·CCK (Gastrin)	·Endothelin	·Melanocortin	·Neuropeptide Y	·Neurotensin	·Opioid	Somatostatin
CLASS	•Class I Rhodopsin like																									

									TI ⁻ TR	TLE: ANS VEN	ME SMEI TOR	ETHO MBR (S):	FILI ODS RANE CA SER	OF I	DEN ONI N L	ITIF STS OO	YING MIS	RE , ET	DUC		003 Inte	ERN.	ALIZ	ATIO	N		Suc	ET 2	of 6
	Depression, Analgesic	Anti-coagulant, Anti-inflammatory	Anti-diuretic, Diabetic Complications	Analgesics, Alzheimer's		Infertility	Infertility	Thyroidism, Metabolism		Ophthalmic Diseases	Olfactory Diseases	-	Cardiovascular, Analgesic	Cancer, Anti-Inflammatory	Cancer	Asthma, Rheumatoid Arthritis	Cardiovascular	Cardiovascular, Respiratory		Cardiovascular, Respiratory	Cardiovascular, Respiratory	Analgesics, Memory	Anti-inflammatory, Anti-asthmatic			Prostate Cancer, Endometriosis	Metabolic Regulation	Š	Regulation of Circadian Cycle
	Neurohormone	Coagulation	Water Balance	Neurotransmitter		Endocrine	Endocrine	Endocrine		Photoreception	Smell		Vasodilation, Pain	Inflammation	Cell proliferation	Inflammation	Platelet Regulation	Vasoconstriction		Multiple Effects	Relaxes Muscle	Sensory Perception	Inflammation			y Reproduction	Thyroid Regulation	Neuroendocrine	Neuroendocrine
	Brain Nerves	Platelets, Blood Vessels	Arteries, Heart, Bladder	Brain, Pancreas		Ovary, Testis	Ovary, Testis	Thyroid		Eye	Nose		Arterial, Gastrointestinal	Vessels, Heart, Lung	Most Cells	White Blood Cells, Bronchus	Arterial, Gastrointestinal	Arterial, Bronchus		Vascular, Bronchus	Vascular, Platelets	Brain	Most Peripheral Tissues			Reproductive Organs, Pituitary Reproduction	Pituitary, Brain	Gastrointestinal	Brain, Eye, Pituitary
	3	3	4	1		1	1	1		5	$4(\sim 1000)$		5	2	2		1	_		4	4	2	1			1		1	_
***************************************	(Substance P, NKA ₁)	·Thrombin	·Vasopressin-like	Galanin	·Hormone protein	·Follicle stimulating hormone	·Lutropin-choriogonadotropic	·Thyrotropin	·(Rhod)opsin	·Opsin	·Olfactory	Prostanoid	·Prostaglandin	·Lysophosphatidic Acid	·Sphingosine-1-phosphate	·Leukotriene	·Prostacyclin	·Thromboxane	·Nucleotide-like	·Adenosine	·Purinoceptors	·Cannabis	·Platelet activating factor	·Gonadotropin-releasing	hormone like	·Gonadotropin-releasing hormone	·Thyrotropin-releasing hormone	Growth hormone- inhibiting factor	-Melatonin

·Tachykinin



SHEET 3 OF 60

		ис	TITLE: METHO TRANSMEMBRA INVENTOR(S):	FILING DATE: OCTOBER 24, 2003 DDS OF IDENTIFYING REDUCED INTERNALIZATION ANE AGONISTS CARSON LOOMIS, ET AL. SERIAL NO.: UNASSIGNED
-	Obesity, Gastrointestinal Osteoporosis	Stress, Mood, Obesity Diabetes, Obesity Cardiovascular Cardiovascular, Diabetes, Obesity Neuroendocrine Growth Regulation	Osteoporosis Metabolic Regulation Gastrointestinal	Hearing, Vision Mood Disorders Cataracts, GI Tumors
	Digestion Calcium Resorption	Neuroendocrine Sugar/Fat Metabolism Gluconeogenesis Gluconeogenesis Brain	Calcium Regulation Metabolism Motility	Sensory Perception Neurotransmitter Calcium Regulation
	Gastrointestinal, Heart Bone, Brain	Adrenal, Vascular, Brain Adrenals, Fat Cells Liver, Fat Cells, Heart Pancreas, Stomach, Lung	Bone, Kidney Brain, Pancreas, Adrenals Gastrointestinal	Brain Brain Neurotransmitter Parathyroid, Kidney, GI Tract Calcium Regulation
		1 1 1 1 ne ne		7 1 1
	Secretin -Calcitonin -Corticotropin releasing	factor/urocortin Gastric inhibitory peptide (GIP) Glucagon Glucagon-like Peptide 1 (GLP-1) Growth hormone-releasing hormone	PACAP Vasoactive intestinal polypeptide (VIP)	·Metabotropic Glutamate ·GABA _B ·Extracellular Calcium Sensing
•Class II Secretin like			H	Class

TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION

TRANSMEMBRANE AGONISTS

INVENTOR(S): CARSON LOOMIS, ET AL.
APPLICATION SERIAL NO.: UNASSIGNED

SHEET 4 OF 60

Figure 2

G protein-coupled receptors:

(Division into Class A Or Class B)

1. A1 adenosine receptor [Homo sapiens]. ACCESSION AAB25533 npivyaf riqkfrvtfl kiwndhfrcq pappidedlp eerpdd

Class A

- 2. adrenergic, alpha -1B-, receptor [Homo sapiens]. ACCESSION NP_000670 npiiypcsskefkrafvrilgeqergrgrrrrrrrrlggcaytyrpwtrggslersqsrkdslddsgsclsgsqrtlpsaspspgylgrgap ppvelcafpewkapgallslpapeppgrrgrhdsgplftfklltepespgtdggasnggceaaadvangqpgfksnmplapgqf Class A
- **3. adrenergic receptor alpha-2A** [Homo sapiens]. ACCESSION AAG00447 npviytifnhdfrrafkkilcrgdrkriv

Class A

4. alpha-2B-adrenergic receptor - human. ACCESSION A37223 npviytifnqdfrrafrrilcrpwtqtaw

Class A

5. alpha-2C-adrenergic receptor - human. ACCESSION A31237 npviytvfnqdfrpsfkhilfrrrrgfrq

Class A

6. beta-1-adrenergic receptor [Homo sapiens]. ACCESSION NP_000675 npiiycrspdfrkafqgllccarraarrrhathgdrprasgclarpgpppspgaasdddddvvgatpparllepwagcnggaaads d ssldepcrpgfaseskv

Class A

7. beta-2 adrenergic receptor. ACCESSION P07550 npliyerspdfriafqellclrrsslkaygngyssngntgeqsgyhveqekenkllcedlpgtedfvghqgtvpsdnidsqgrncstnd sll

Class A

8. dopamine receptor D1 [Homo sapiens]. ACCESSION NP_000785 npiiyafnadfrkafstllgcyrlcpatnnaietvsinnngaamfsshheprgsiskecnlvyliphavgssedlkkeeaagiarplekls palsvildydtdvslekiqpitqngqhpt

Class A

9. **D(2) dopamine receptor.** ACCESSION P14416 npiiyttfniefrkaflkilhc

Class A

TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION TRANSMEMBRANE AGONISTS

INVENTOR(S): CARSON LOOMIS, ET AL.
APPLICATION SERIAL NO.: UNASSIGNED

SHEET 5 OF 60

10. d3 dopamine receptor - human. ACCESSION G01977 npviyttfniefrkaflkilsc

Class A

11. **dopamine receptor D4** - human. ACCESSION DYHUD4 npviytvfnaefrnvfrkalracc

Class A

12. dopamine receptor D5 - human. ACCESSION DYHUD5 npviyafnadfqkvfaqllgcshfcsrtpvetvnisnelisynqdivfhkeiaaayihmmpnavtpgnrevdndeeegpfdrmfqi yqtspdgdpvaesvweldcegeisldkitpftpngfh

Class A

muscarinic acetylcholine receptor M1 [Homo sapiens]. ACCESSION NP_000729 npmcyalcnkafrdtfrllllcrwdkrrwrkipkrpgsvhrtpsrqc

Class A

14. muscarinic acetylcholine receptor M2 [Homo sapiens]. ACCESSION NP_000730 npacyalcnatfkktfkhllmchyknigatr

Class A

15. muscarinic acetylcholine receptor M3 [Homo sapiens].
npvcyalcnktfrttfkmlllcqcdkkkrrkqqyqqrqsvifhkrapeqal
Class A

16. muscarinic acetylcholine receptor M4 [Homo sapiens]. ACCESSION NP_000732 npacyalcnatfkktfrhlllcqyrnigtar

Class A

17. m5 muscarinic receptor. locus HUMACHRM ACCESSION AAA51569 npicyalcnrtfrktfkmlllcrwkkkkveeklywqgnsklp

Class A

5-hydroxytryptamine (serotonin) receptor 1A [Homo sapiens]. ACCESSION BAA90449 npviyayfnkdfqnafkkiikckf

Class A

19. 5-hydroxytryptamine (serotonin) receptor 1B [Homo sapiens]. ACCESSION BAA94455 npiiytmsnedfkqafhklirfkcts

Class A

5-hydroxytryptamine (serotonin) receptor 1E [Homo sapiens]. ACCESSION BAA94458 npllytsfnedfklafkklircre

Class A

21. OLFACTORY RECEPTOR 6A1. ACCESSION 095222

TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION

TRANSMEMBRANE AGONISTS

INVENTOR(S): CARSON LOOMIS, ET AL.
APPLICATION SERIAL NO.: UNASSIGNED

SHEET 6 OF 60

Figure 2 page 3

npiiyelmqevkralceilhlyqhqdpdpkkgsmv Class A

22. OLFACTORY RECEPTOR 2C1. ACCESSION 095371 npliytlrnmevkgalrrllgkgrevg

Class A

- 23. angiotensin receptor 1 [Homo sapiens]. ACCESSION NP_033611 nplfygflgkkfkryflqllkyippkakshsnlstkmstlsyrpsdnvssstkkpapefeve Class B
- 24. angiotensin receptor 2 [Homo sapiens]. ACCESSION NP_000677 npflycfvgnrfqqklrsvfrvpitwlqgkresmscrkssslremetfvs

 Class B
- 25. interleukin 8 receptor beta (CXCR2) [Homo sapiens]. ACCESSION NM_001557 NPLIYAFIGQKFRHGLLKILAIHGLISKDSLPKDSRPSFVGSSSGHTSTTL Class B
- 26. cx3c chemokine receptor 1 (cx3cr1) (fractalkine receptor)
 ACCESSION P49238
 npliyafagekfrrylyhlygkclavlcgrsvhvdfsssesqrsrhgsvlssnftyhtsdgdallll
 Class B
- 27. neurotensin receptor human. ACCESSION S29506 n pilynlvsanfrhiflatlaclcpvwrrrrkrpafsrkadsvssnhtlssnatretly Class B
- 28. SUBSTANCE-P RECEPTOR (SPR) (NK-1 RECEPTOR) (NK-1R). ACCESSION P25103 npiiycclndrfrlgfkhafrccpfisagdyeglemkstrylqtqgsvykvsrlettistvvgaheeepedgpkatpssldltsncssrsd sktmtesfsfssnvls

Class B

- 29. vasopressin receptor type 2 [Homo sapiens]. ACCESSION AAD16444 npwiyasfsssvsselrsllccargrtppslgpqdescttassslakdtss
 Class B
- 30. thyrotropin-releasing hormone receptor human. ACCESSION JN0708 npviynlmsqkfraafrklcnckqkptekpanysvalnysvikesdhfsteldditvtdtylsatkvsfddtclasevsfsqs Class B
- 31. oxytocin receptor human. ACCESSION A55493
 npwiymlftghlfhelvqrflccsasylkgrrlgetsaskksnsssfvlshrsssqrscsqpsta
 Class B

TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION

TRANSMEMBRANE AGONISTS

INVENTOR(S): CARSON LOOMIS, ET AL. APPLICATION SERIAL NO.: UNASSIGNED

SHEET 7 OF 60

Figure 2 page 4

- 32. neuromedin U receptor 1 [Homo sapiens]. ACCESSION AAG24793 npvlyslmssrfretfqealclgacchrlrprhsshslsrmttgstlcdvgslgswvhplagndgpeaqqetdps Class B
- 33. gastrin receptor. ACCESSION AAC37528
 nplvycfmhrrfrqacletcarccprpprarpralpdedpptpsiaslsrlsyttistlgpg
 Class B
- 34. galanin receptor 3 [Homo sapiens]. ACCESSION 10879541 nplvyalasrhfrarfirlwpcgrrrrhrarralrrvrpassgppgcpgdarpsgrllagggqgpepregpvhggeaargpe Class A
- 35. edg-1 human. ACCESSION A35300
 npiiytltnkemrrafirimscckcpsgdsagkfkrpiiagmefsrsksdnsshpqkdegdnpetimssgnvnsss
 Class A
- 36. central cannabinoid receptor [Homo sapiens]. ACCESSION NP_057167 npiiyalrskdlrhafrsmfpscegtaqpldnsmgdsdclhkhannaasvhraaescikstvkiakvtmsvstdtsaeal Class A
- 37. delta opioid receptor human. ACCESSION I38532 npvlyafldenfkrcfrqlcrkpcgrpdpssfsrpreatarervtactpsdgpgggraa Class A
- 38. proteinase activated receptor 2 (PAR-2) human. ACCESSION P55085 dpfvyyfvshdfrdhaknallcrsvrtvkqmqvsltskkhsrksssyssssttvktsy


 Class B
- 39. vasopressive intestinal peptide receptor (VIPR) rat. ACCESSION NM_012685
 NGEVQAELRRKWRRWHLQGVLGWSSKSQHPWGGSNGATCSTQVSMLTRVSPSARR
 SSSFQAEVSLV

Class B

	Α	В	С
1	GPCR Agonist	Generic Name	Brand Name
2	5-HT		
3	5-HT-1B/1D	Zolmitriptan	Zomig
4	<u> </u>	Rizatriptan	Maxalt
5		Eletriptan	Relpax
6		Trazodone	Desyrel
7	5-HT-1D	Sumatriptan	Imitrex (P)
8		Naratriptan	Amerge
9		Almotriptan	Axert
10	5-HT-1B/1A	Frovatriptan	Frova
11			
12	5-HT-1A	Buspirone	BuSpar
13	5-HT-1A	Buspirone	Generic
14	5-HT-1A	Ziprasidone	Geodon
15			
16	5-HT-4	Tegaserod	Zelnorm
17	5-HT-4	Mosapride	Gasmotin
18	5-HT-4	Cisapride	Propulsid
19			
20	5-HT-2A/2C	Clozapine	Clozaril
21			
22	5-HT-2 / Dopa D1	Femoldopam	Corlopam
23		<u> </u>	
24	5-HT/ Opioid u	Tramadol	Ultram
25	5-HT/ Opioid u	Tramadol	Ultracet
26	5-HT/ Opioid u	Tramadol	Generic
27			
28	Opioid		
29	Opioid	Codeine	Generic
30		Hydrocodone	Generic
31		Hydromorphone	Dilaudid
32		Levorphanol	Levo-Dromoran
33		Morphine	MS Contin
34	-	Morphine	Generic
35		Oxycodone Oxycodone	OxyContin Generic
36		Oxycodone/APAP	Numorphan
37		Oxymorphone Alfentanil	Alfenta
38 39		Fentanyl	Duragesic
40		Fentanyl	Sublimaze
40		Meperidine	Demerol
41		Sufentanil	Sufenta
43		Levomethadyl	Orlaam
44		Methadone	Dolophine
45		Propoxyphene	Darvon
46		Buprenorphine	Transtec
47		Remifentanil	Ultiva
48			
49	5-HT/ Opioid u	Tramadol	Ultram
50		Tramadol	Ultracet
51	5-HT/ Opioid u	Tramadol	Generic
<u> </u>			
52		Fig 3, page 1 of	3


	A	В	С
1	GPCR Agonist	Generic Name	Brand Name
53	ADO		
	ADO (mixed)	Adenosine	Adenocard
55	ADO (IIIAOU)	Adenosine	Adenoscan
56			
	Adreneenter		
57	Adrenoceptor	Mathydahanidata	Generic
58	Adrenoceptor	Methylphenidate	
59	Beta (mixed)	Isoproterenol	Isuprel
60		Ephedrine	Generic
61	<u> </u>	Mephentermine	Wyamine
62	Beta-1	Norepinephrine	Levophed
63	D		
64	Beta-2	Salmeterol	Serevent
		Salmeterol/	
65		fluticasone	Advair
66		Albuterol, Aerosol	Generic
67		Albuterol, Sulfate	Generic
68		Albuterol	Proventil
69		Bitolterol	Tornalate
70		Isoetharine	Isoetharine
71		Metaproterenol	Alupent
72		Pirbuterol	Maxair
73		Formoterol	Foradil
74		Formoterol,	Oxis
75		Albuterol	Ventolin HFA
76		Bambuterol	Bambec
		Salbutamol	Inspiryl Turbuhaler
77			
78		Terbutaline	Brethine
79		Terbutaline	Terbutaline
		loratadine/	Claritin-D
80	H1 (-) / Beta-2 (+)	pseudoephedrine	
		Fexofenadine/	Allegra-D
81	H1 (-) / Beta-2 (+)	pseudoephedrine	
82		Terbutaline	Brethine
83	Alpha-Beta (mixed)	Metaraminol	Aramine
84		Epinephrine	Generic
85	Alpha (mixed)	Methoxamine	Vasoxyl
86		Phenyephrine	Neo-Synephrine
87	Alpha-1	Modafinil	Provigil
88		Midodrine	ProAmatine
89			
90	Alpha-2	Guanfacine	Tenex
91	· · · · · · · · · · · · · · · · · · ·	Tizanidine SR	Sirdalud CR
92		Moxonidine	Physiotens
93		Dexmedetomidine	Precedex
94		Brimonidine	Alphagen
95		Apraclonidine	lopidine
٣		7.00.0	1:
96		Fig 3, page 2 of 3	
_ 30	L	i ig J, page 2 Ul J	' [

	Α	В	С
1	GPCR Agonist	Generic Name	Brand Name
97			
98	Acetylcholine	Bethanechol	Generic
99	Muscarinic AC	Pilocarpine	Salagen
100	Muscarinic AC	Levetiracetam	Керрга
101			
102	Dopamine		
103	Dopamine (mixed)	Dopamine	Intropin
104		Femoldopam	Corlopam
105	D2	Apomorphine	Ixense
106	D2/D3	Ropinirole	Requip
107	D2/D3	Pramipexole	Mirapex
	D2/D3	Amisulpride	Solian
109	D2 Type	Bromocriptine	Parlodel
110	D1/D2	Pergolide	Permax
111			
	Prostaglandin F2a	Latanoprost	Xalatan
112	(PG F2a)	·	
	Prostaglandin F2a	Unknown	Travatan
113	(PG F2a)		
	Prostaglandin E1	Alprostadil	Befar
114	(PGE1)		
115			
	Gonadotropin-	LHRH agonist	TRELSTAR LA
	releasing hormone		
116	(GnRH)		
117	GnRH	Leuprolide	Lupron Depot
118			
119			
120	Calcitonin	Calcitonin	
121		Fig 3, page 3 of 3	




TRANSMEMBRANE AGONISTS
INVENTOR(S): CARSON LOOMIS, ET AL.
APPLICATION SERIAL NO.: UNASSIGNED

SHEET 12 OF 60




TRANSMEMBRANE AGONISTS
INVENTOR(S): CARSON LOOMIS, ET AL.
APPLICATION SERIAL NO.: UNASSIGNED

SHEET 13 OF 60



TRANSMEMBRANE AGONISTS


INVENTOR(S): CARSON LOOMIS, ET AL. APPLICATION SERIAL NO.: UNASSIGNED




APPLICATION FILING DATE: OCTOBER 24, 2003
TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
TRANSMEMBRANE AGONISTS

INVENTOR(S): CARSON LOOMIS, ET AL. APPLICATION SERIAL NO.: UNASSIGNED

SHEET 15 OF 60




TRANSMEMBRANE AGONISTS
INVENTOR(S): CARSON LOOMIS, ET AL.
APPLICATION SERIAL NO.: UNASSIGNED



TRANSMEMBRANE AGONISTS


INVENTOR(S): CARSON LOOMIS, ET AL.
APPLICATION SERIAL NO.: UNASSIGNED

SHEET 17 OF 60




APPLICATION SERIAL NO.: UNASSIGNED

SHEET 18 OF 60




SHEET 19 OF 60



APPLICATION FILING DATE: OCTOBER 24, 2003
TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
TRANSMEMBRANE AGONISTS


INVENTOR(S): CARSON LOOMIS, ET AL. APPLICATION SERIAL NO.: UNASSIGNED

SHEET 20 OF 60



TRANSMEMBRANE AGONISTS INVENTOR(S): CARSON LOOMIS, ET AL. APPLICATION SERIAL NO.: UNASSIGNED


SHEET 21 OF 60



TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
TRANSMEMBRANE AGONISTS

INVENTOR(S): CARSON LOOMIS, ET AL. APPLICATION SERIAL NO.: UNASSIGNED


SHEET 22 OF 60



TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION


TRANSMEMBRANE AGONISTS
INVENTOR(S): CARSON LOOMIS, ET AL. **APPLICATION SERIAL NO.: UNASSIGNED**

SHEET 23 OF 60




TRANSMEMBRANE AGONISTS
INVENTOR(S): CARSON LOOMIS, ET AL. APPLICATION SERIAL NO.: UNASSIGNED

SHEET 24 OF 60




APPLICATION FILING DATE: OCTOBER 24, 2003
TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
TRANSMEMBRANE AGONISTS
INVENTOR(S): CARSON LOOMIS, ET AL.
APPLICATION SERIAL NO.: UNASSIGNED **SHEET 25 OF 60** 1.0E-06 1.0E-06 GPCR signaling and Translocation, human GPCR, GPCR signaling and Translocation, human GPCR, U2OS cells, 120 min after stimulation with U2OS cells, 120 min after stimulation with 1.0E-08 1.0E-08 Compound 5 - Experiment Compound 6 - Experiment 1 1.0E-10 Peptide(M) 1.0E-10 Peptide(M) 1.0E-12 1.0E-12 1.0E-14 1.0E-14 control compound control compound នុ 8 -50 ස 8 % Max Response with % Max Response with 1.0E-06 1.0E-06 GPCR signaling and Translocation, human GPCR, ▲ Translocation GPCR signaling and Translocation, human GPCR, Signaling U2OS cells, 60 min after stimulation with Compound 5 - Experiment 1 U2OS cells, 60 min after stimulation with 1.0E-08 Compound 6 - Experiment 1 1.0E-10 1 Peptide(M) 1.0E-10 Peptide(M) 1.0E-12 1.0E-12 1.0E-14 4 1.0E-1 % Max Response with control compound S 5 5 % Max Response with control compound 8 8 8 5 5 នុ Ŗ 8 1.0E-06 1.0E-06 GPCR signaling and Translocation, human GPCR, GPCR signaling and Translocation, human GPCR, ▲ Translocation ▲ Transfocation Signaling Signating U2OS cells, 30 min after stimulation with U2OS cells, 30 min after stimulation with 1.0E-08 1.0E-08 Compound 5 - Experiment 1 Compound 6 - Experiment 1 1.0E-10 Peptide(M) 1.0E-10 Peptide(M) 1.0E-12 1.0E-12 1.0E-14 1.0E-14 5-F 5-E control compound Control compound. Ŗ 8 120 22 5 នុ % Max Response with % Max Response with

APPLICATION FILING DATE: OCTOBER 24, 2003 TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION TRANSMEMBRANE AGONISTS
INVENTOR(S): CARSON LOOMIS, ET AL. APPLICATION SERIAL NO.: UNASSIGNED **SHEET 26 OF 60** 1.0E-06 1.0E-06 GPCR signaling and Translocation, human GPCR, U2OS cells, 120 min after stimulation with 1.0E-08 1.0E-08 Compound 7 - Experiment 1 Compound 8 - Experiment 1 1.0E-10 Peptide(M) 1.0E-10 Peptide(M) 1.0E-12 1.0E-12 1.0E-14 1.0E-14 bnuoqmoo lottnoo 8 8 4 8 control compound. 8 -50 120 នុ 22 % Max Response with % Max Response with 1.0E-06 1.0E-06 GPCR signaling and Translocation, human GPCR, U2OS cells, 60 min after stimulation with 1.0E-08 1.0E-08 Compound 8 - Experiment 1 Compound 7 - Experiment 1 1.0E-10 Peptide(M) 1.0E-10 Peptide(M) 1.0E-12 1.0E-12 Signating 1.0E-14 % Max Response with control compound 2 6 8 8 8 % Max Response with configuration of the control compound of the control compound of the control 2 8 1.0E-06 1.0E-06 1.0E-08 1.0E-08 1.0E-10
Peptide(M) 1.0E-10 Peptide(M)




TRANSMEMBRANE AGONISTS
INVENTOR(S): CARSON LOOMIS, ET AL. **APPLICATION SERIAL NO.: UNASSIGNED**

SHEET 27 OF 60




APPLICATION FILING DATE: OCTOBER 24, 2003
TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION TRANSMEMBRANE AGONISTS
INVENTOR(S): CARSON LOOMIS, ET AL. **APPLICATION SERIAL NO.: UNASSIGNED SHEET 28 OF 60** 1.0E-06 1.0E-06 GPCR signaling and Translocation, human GPCR U2OS cells, 120 min after stimulation with Compound 12. 1.0E-08 1.0E-08 1.0E-10 Peptide(M) 1.0E-10 Peptide(M) Experiment 1 1.0E-12 1.0E-12 1.0E-14 1.0E-14 ద్గ 8 8 8 ಜ bnuogmoo lottnoo 8 8 8 5 8 8 8 8 % Max Response with control compound % Max Response with 1.0E-06 1.0E-06 U2OS cells, 60 min after stimulation with 1.0E-08 1.0E-08 Compound 12 - Experiment 1 1.0E-10 Peptide(M) 1.0E-10 Peptide(M) 1.0E-12 1.0E-12




TRANSMEMBRANE AGONISTS
INVENTOR(S): CARSON LOOMIS, ET AL.
APPLICATION SERIAL NO.: UNASSIGNED

SHEET 29 OF 60



TRANSMEMBRANE AGONISTS
INVENTOR(S): CARSON LOOMIS, ET AL.
APPLICATION SERIAL NO.: UNASSIGNED


SHEET 30 OF 60



TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION

TRANSMEMBRANE AGONISTS
INVENTOR(S): CARSON LOOMIS, ET AL. **APPLICATION SERIAL NO.: UNASSIGNED**


SHEET 31 OF 60



TRANSMEMBRANE AGONISTS


INVENTOR(S): CARSON LOOMIS, ET AL. APPLICATION SERIAL NO.: UNASSIGNED

SHEET 32 OF 60




TRANSMEMBRANE AGONISTS INVENTOR(S): CARSON LOOMIS, ET AL. APPLICATION SERIAL NO.: UNASSIGNED

SHEET 33 OF 60




SHEET 34 OF 60



TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION TRANSMEMBRANE AGONISTS

INVENTOR(S): CARSON LOOMIS, ET AL. APPLICATION SERIAL NO.: UNASSIGNED


SHEET 35 OF 60



TRANSMEMBRANE AGONISTS

INVENTOR(S): CARSON LOOMIS, ET AL.
APPLICATION SERIAL NO.: UNASSIGNED

SHEET 36 OF 60




APPLICATION FILING DATE: OCTOBER 24, 2003

TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION

TRANSMEMBRANE AGONISTS
INVENTOR(S): CARSON LOOMIS, ET AL. APPLICATION SERIAL NO.: UNASSIGNED


SHEET 37 OF 60



TRANSMEMBRANE AGONISTS

INVENTOR(S): CARSON LOOMIS, ET AL.
APPLICATION SERIAL NO.: UNASSIGNED


SHEET 38 OF 60



TRANSMEMBRANE AGONISTS

INVENTOR(S): CARSON LOOMIS, ET AL. APPLICATION SERIAL NO.: UNASSIGNED


SHEET 39 OF 60




TRANSMEMBRANE AGONISTS

INVENTOR(S): CARSON LOOMIS, ET AL. APPLICATION SERIAL NO.: UNASSIGNED


SHEET 40 OF 60





APPLICATION FILING DATE: OCTOBER 24, 2003
TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
TRANSMEMBRANE AGONISTS
INVENTOR(S): CARSON LOOMIS, ET AL.


APPLICATION SERIAL NO.: UNASSIGNED




APPLICATION FILING DATE: OCTOBER 24, 2003


TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION

TRANSMEMBRANE AGONISTS







TRANSMEMBRANE AGONISTS



TRANSMEMBRANE AGONISTS




TRANSMEMBRANE AGONISTS



APPLICATION FILING DATE: OCTOBER 24, 2003
TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION
TRANSMEMBRANE AGONISTS
INVENTOR(S): CARSON LOOMIS, ET AL.
APPLICATION SERIAL NO.: UNASSIGNED


SHEET 47 OF 60




APPLICATION FILING DATE: OCTOBER 24, 2003


TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION

TRANSMEMBRANE AGONISTS







TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION



TRANSMEMBRANE AGONISTS




TRANSMEMBRANE AGONISTS




TRANSMEMBRANE AGONISTS

INVENTOR(S): CARSON LOOMIS, ET AL. APPLICATION SERIAL NO.: UNASSIGNED


SHEET 53 OF 60





TRANSMEMBRANE AGONISTS




TRANSMEMBRANE AGONISTS








TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION TRANSMEMBRANE AGONISTS



APPLICATION FILING DATE: OCTOBER 24, 2003

TITLE: METHODS OF IDENTIFYING REDUCED INTERNALIZATION

TRANSMEMBRANE AGONISTS



TRANSMEMBRANE AGONISTS
INVENTOR(S): CARSON LOOMIS, ET AL.
APPLICATION SERIAL NO.: UNASSIGNED

SHEET 60 OF 60